Jonas Bergh

Research interests

Publications

• Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.017

• Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.11.016

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.09.159

• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00288-6

• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.09.010

• Pembrolizumab for Early Triple-Negative Breast Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1910549

• Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)33137-4

• Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing

  Nature Communications · 2018 · https://doi.org/10.1038/s41467-018-07582-3

• 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy192

• Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30777-5

• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  Annals of Oncology · 2017 · 10.1093/annonc/mdx308

• 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw544

• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(13)62422-8

• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt303

• 1st International consensus guidelines for advanced breast cancer (ABC 1)

  The Breast · 2012 · https://doi.org/10.1016/j.breast.2012.03.003

• Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.25.5729

• Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2010.30.8213

• Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2006.07.1522

• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-2765

• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

  The Lancet · 2007 · 10.1016/s0140-6736(07)60028-2

• Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

  JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj052

• Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2006 · 10.1093/jnci/djj329

Current projects

No projects listed.